MIA experts collaborate on groundbreaking research
16 January 2019
In another collaborative effort in our quest to reach zero deaths from melanoma, Melanoma Institute Australia (MIA) has contributed its expertise to an exciting new study published in the prestigious journal Nature.
Led by researchers from Perth’s Telethon Kids Institute and The University of Melbourne, the study aimed to discover the specific mechanisms behind immune-mediated equilibrium – the reason malignant cells can remain dormant in a patient for years without manifesting as disease.
MIA’s Co-Medical Director, Professor Richard Scolyer, post-doctoral researcher, Dr James Wilmott, and collaborator, Dr Mainthan Palendira, were all responsible for intellectual input and data interpretation. MIA PhD student Jarem Edwards assisted in performing experiments for the study and analysing the resultant data.
The study found that a particular type of immune cell - tissue-resident memory (TRM) T cells - were responsible for patrolling melanoma cells and keeping them in check. When they removed this type of cell from the body of mice with melanoma, the melanoma cells were re-established and allowed to grow.
The hope is that this research will pave the way for investigators to manipulate this mechanism and control and maintain melanoma, and other cancers, in a dormant state for life, effectively curing patients.
Image: Imaging of cells keeping cancer in dormancy - Jason Waithman research.png (Telethon Kids Institute)
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.